Allakos, a US-based developer of antibodies to treat diseases that involve the excess production of inflammatory cells, received $10m on Tuesday from existing investors Novo Ventures and Roche Ventures, which act as the corporate venturing units of pharmaceutical companies Novo and Roche respectively, Alta Partners and RiverVest Venture Partners. The funding follows a $32m series A round raised in December 2012.

Broadcaster BskyB invested $5m in US-based native advertising company Sharethrough on Monday as part of a $10m series D…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?